Women’s Genetic Signature
RMA is working with a biotechnology company, Celmatix, on a study focused on the genetic and phenotypic risk factors underlying female infertility. The study’s goal is to discover genetic sequences and/or mutations within female patients which may be linked to their fertility. The findings from the study are expected to alleviate genetic risk factors for a number of fertility issues at an earlier stage and foster better treatment regimens for future IVF patients.
To learn more, click here.